Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Successful Completion of Biomedical Catalyst Programme Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled...
Triggers milestone payment from Mylan Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory...
First full presentation of data from randomised clinical study of glycopyrronium bromide made using Prosonix' novel particle-engineering technology...
Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced that it...
First clinical data from PSX1002, a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting muscarinic ...
PSX1002 is a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA)...
Brings further international experience in the development and commercialisation of respiratory medicines Prosonix, an innovative speciality...
First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle...
Prosonix (Oxford, UK) announced that it has signed a Collaborative Research Agreement with Imperial College London to accelerate the development of...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.